Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
03.07. | BioAtla, Inc.: BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European ... | 107 | GlobeNewswire (Europe) | Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients... ► Artikel lesen | |
20.06. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.06. | BioAtla reports promising trial results for cancer drug | 4 | Investing.com | ||
16.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.05. | BioAtla stock holds $1 target, JMP affirms Market Outperform | 2 | Investing.com | ||
06.05. | BioAtla files to sell 9.68M shares of common stock for holders | 3 | Seeking Alpha | ||
06.05. | BioAtla, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
06.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
BIOATLA Aktie jetzt für 0€ handeln | |||||
05.05. | A Preview Of BioAtla's Earnings | 3 | Benzinga.com | ||
24.04. | BioAtla, Inc.: BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
23.04. | BioAtla, Inc.: BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | 2 | GlobeNewswire (USA) | ||
21.04. | BioAtla stock holds $1 target, Market Outperform rating | 3 | Investing.com | ||
31.03. | BioAtla stock price target cut to $1 by Citizens JMP | 2 | Investing.com | ||
28.03. | BioAtla stock price target cut to $10 at BTIG, retains Buy rating | 4 | Investing.com | ||
28.03. | BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody | 1 | FierceBiotech | ||
27.03. | BioAtla announces 30% workforce reduction | 3 | Seeking Alpha | ||
27.03. | BioAtla, Inc.: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress | 202 | GlobeNewswire (Europe) | CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing... ► Artikel lesen | |
27.03. | BioAtla, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
26.03. | Earnings Outlook For BioAtla | 4 | Benzinga.com | ||
20.03. | BioAtla, Inc.: BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,230 | -16,44 % | Evotec-Aktie mit Kursgewinnen (7,346 €) | Im Plus liegt derzeit der Anteilsschein von Evotec . Das Papier kostete zuletzt 7,35 Euro. Heute hat sich am deutschen Aktienmarkt das Wertpapier von Evotec zwischenzeitlich um 3,41 Prozent verteuert.... ► Artikel lesen | |
BB BIOTECH | 34,600 | -0,86 % | Zwischen Aufbruch und Wandel: Biotech im Check: Wo liegen die Chancen? - BB Biotech: Diversifizierung innerhalb einer Aktie | Steht die Biotech-Branche vor einem strukturellen Wandel? Enormes Innovationspotenzial und gute Voraussetzungen für M&A-Aktivitäten könnten Schwung in den Sektor bringen. Wie geht es eigentlich der... ► Artikel lesen | |
CUREVAC | 4,582 | -0,65 % | Blueprint, Verona, CureVac & Co: Biotechs im Übernahme-Fieber - jetzt Comeback-Chance nutzen | Das Übernahmekarussell im Biotechnologie-Sektor kommt immer mehr in Fahrt. Zuletzt schnappte sich Merck & Co Verona Pharma. Bereits zuvor griff BioNTech bei CureVac zu. Und auch Sanofi zeigte sich auf... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,150 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
BIOXXMED | 0,310 | -24,39 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,210 | -0,82 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
OCUGEN | 0,881 | +2,47 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
INFLARX | 0,739 | +1,51 % | InflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement | JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 11,160 | +3,24 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIO-GATE | 1,010 | -2,88 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,401 | +0,75 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
VAXART | 0,350 | 0,00 % | OTC Markets Group Welcomes Vaxart, Inc. to OTCQX | NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX:... ► Artikel lesen | |
BURCON NUTRASCIENCE | 1,690 | -3,98 % | Burcon NutraScience Corporation: Burcon to Showcase Chipotle Black Bean Protein Hummus at 2025 IFT FIRST Annual Event & Expo | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen |